Form DEFR14A - Revised definitive proxy soliciting materials:
SEC Accession No. 0001193125-23-156608
Filing Date
2023-05-30
Accepted
2023-05-30 16:23:00
Documents
5

Document Format Files

Seq Description Document Type Size
1 DEFR14A d507914ddefr14a.htm DEFR14A 40019
2 GRAPHIC g507914dsp010.jpg GRAPHIC 140843
3 GRAPHIC g507914dsp011.jpg GRAPHIC 85323
4 GRAPHIC g507914g01l01.jpg GRAPHIC 42517
5 GRAPHIC g507914g01s02.jpg GRAPHIC 22816
  Complete submission text file 0001193125-23-156608.txt   433948
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

EIN.: 825125532 | Fiscal Year End: 1231
Type: DEFR14A | Act: 34 | File No.: 001-41551 | Film No.: 23976765
SIC: 2834 Pharmaceutical Preparations